tries [4] . As of July 2005, a total of 179 cases of variant CJD were reported world wide, including 156 cases in the United Kingdom, 13 cases in France, 3 cases in Ireland, and 1 case in each of Canada, Italy, Japan, The Netherlands, Saudi Arabia, and the United States [1, 5, 6] . Cases of variant CJD in 1 of the patients in Ireland and in patients in Canada, Japan, and the United States were attributed to BSE exposure during each patient's past residence in the United Kingdom. The Japanese patient with variant CJD spent ∼24 days in the United Kingdom, indicating that long term cumulative exposure to the BSE agent may not be necessary to contract the disease. In addition, some of the cases of variant CJD in France and the cases in The Netherlands and Saudi Arabia may have resulted from consumption of imported BSE-contaminated cattle products from the United Kingdom.
The classic form of CJD can be distin guished from variant CJD by the age distribution (median age at death, 68 and 28 years, respectively), clinical presentation and progression, and codon 129 polymorphism of the patients, and by the characteristic neuroimaging, neuropathologic analysis, and immunodiagnostic profiling (table 1) [3] . Patients with classic CJD commonly present with dementia, ataxia, behavioral changes, and/or visual deficits [7] . Other less prominent signs, such as involuntary movements, also may be noted at the time of clinical presentation. As the disease progresses, patients typically develop a variety of neurologic deficits, in cluding worsening dementia, cerebellar dysfunction, myoclonus, pyramidal and extrapyramidal signs, and akinetic mutism; death usually occurs at a median of 4-6 months after onset of illness. Most patients with CJD have a characteristic electroencephalogram (EEG) finding of periodic sharp waves. In some patients, abnormal findings of MRI, primarily in cortical regions of the brain and the basal ganglia, are believed to be suggestive of a CJD diagnosis [8, 9] . Elevated levels of 14 3-3 protein in the CSF may also aid in the diagnosis of CJD, particularly if patients manifest with the typical clinical signs and progression. Elevation of the 14-3-3 protein in the CSF is a marker for rapid neuronal death, and this marker can occur in other conditions associated with rapid cell death (e.g., intracerebral hemorrhages and encephalitis) [10] . The clinical manifestations of some of these conditions could mimic CJD and, thus, present a diagnostic challenge to clinicians.
A definitive diagnosis of CJD requires analysis of brain tissues obtained by either biopsy or autopsy. In this issue of Clinical Infectious Diseases, Jara et al. [11] report that a CSF 14-3-3 test was performed for less than one-half of patients with CJD identified during 1991-2001 in Massachu setts [11] . In contrast, all patients with CJD whose medical records were reviewed had an EEG assessment, and 84% of patients underwent MRI. The characteristic EEG findings were reported for 84% of A patient with preclinical variant CJD related to bloodborne transmission was heterozygous for methionine and valine.
c patients with CJD. Brain biopsy or autopsy was performed for more than one-half of the patients with CJD whose medical re cords were reviewed by Jara et al. [11] . As expected, the proportion of patients with CJD for whom brain biopsy was per formed was inversely related to the age of patients. Because brain biopsy is an invasive pro cedure and its diagnostic value depends on successful sampling of a multifocal le sion, it is not routinely advised for patients with a reasonable clinical diagnosis of CJD. Brain biopsy is more useful for pa tients in whom an alternative, potentially manageable condition is suspected. Ade quate CJD infection-control protocols should be in place in hospitals that per form brain biopsy for patients with sus pected CJD. This might help to avoid inadvertent exposure of patients to inad equately sterilized neurosurgical instru ments previously used on patients whose CJD diagnosis becomes apparent after their surgical procedure. Such episodes of exposure have been reported in many hos pitals, resulting in ethical and legal dilem mas, such as whether exposed patients should be informed about any potential risk [1] . Neurosurgical instru ments used on patients with suspected CJD or on patients with no clear diagnosis at the time of craniotomy should be quar antined until the diagnosis is clarified, or they should be decontaminated by use of sterilization protocols recommended for reprocessing CJD-contaminated instru ments [12] .
In 1996-1997, the National Prion Disease Pathology Surveillance Center (NPDPSC) was established by the Centers for Disease Control and Prevention (CDC) in collaboration with the American Association of Neuropathologists to facil itate prion disease surveillance. The NPDPSC provides state-of-the art prion disease diagnostic services to US physi cians without charge. The diagnostic tests performed at the NPDPSC include a CSF 14-3-3 immunoassay, routine histopath ologic analysis, immunohistochemistry, and Western blot and prion protein gene analyses [13] . In 2002, the NPDPSC con firmed a diagnosis of prion disease for ap proximately half of the annual number of expected new cases of CJD in the United States; since then, the number of confir mations per year may have increased, be cause more clinicians became aware of this service. As of April 2005, the NPDPSC had confirmed prion disease in 1046 (60%) of 1747 suspected patients whose brain tissue specimens were examined. Of the 1005 pa tients for whom data were available, 851 (84.7%) had sporadic CJD, 149 (14.8%) had familial prion disease, and 5 (0.5%) had iatrogenic CJD.
In addition, the CDC periodically re views the national multiple cause-of-death data to monitor the trend of CJD-related deaths in the United States. An average annual age-adjusted CJD-related death rate of 0.97 deaths per million persons was reported for the years 1979-1998 [14] . Efforts to increase the number of au topsies among patients suspected of hav ing died of CJD should continue. Post mortem examination of brain tissue specimens not only confirms a diagnosis of CJD, but also makes brain tissue avail able, which is crucial for furthering our understanding of the various subtypes of CJD, for monitoring the occurrence of variant CJD, and for monitoring the pos sibility of animal-to-human transmission of chronic wasting disease, a prion disease endemic in North American deer and elk populations. Availability of brain tissues will also facilitate research of prion disease to better understand the biochemical characteristics of the etiologic agent and its pathogenesis and to help develop morespecific premortem diagnostic tools and disease-specific therapies. Unfortunately, the national trend of decreasing overall percentage of US decedents for whom au topsy is performed is not encouraging. The percentage decreased from 40%-50% of decedents in the 1960s to !6% in 1994 [15] . Neurologists and pathologists sur veyed in California and New York cited cost of autopsy, family reluctance to give consent, and infection-control concerns by pathologists and hospitals as major bar riers to performing autopsies for patients with suspected or clinically diagnosed CJD [16] . These barriers could potentially be surmounted by educating family members about the importance of autopsies, estab lishing a network of pathologists experi enced and willing to perform CJD autop sies, and making available funds to cover the cost of performing autopsies. Such ef forts might be most beneficial if they take into account the places where death oc curred for patients with CJD. For example, Jara et al. [11] reported that ∼39% of CJDrelated deaths in their study occurred in a long-term care facility, 33% of deaths occurred in a hospital, and 28% of deaths occurred at home or in hospice care. Health care workers providing care to ter minally ill patients with CJD in these fa cilities should be encouraged to discuss possible options for autopsy with the at tending physician and their local and state health departments. In addition, brain tis sue specimens obtained by autopsy from patients with suspected or clinically di agnosed CJD should be submitted to the NPDPSC for further analysis. Detailed in formation about the NPDPSC is avail able at its Web site (http://www.cjd surveillance.com).
